EA
KALV

Emerald Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

Emerald Advisers’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.4M Sell
1,264,023
-76,472
-6% -$1.23M 0.81% 55
2025
Q4 		$21.6M Sell
1,340,495
-10,759
-0.8% -$142K 0.67% 69
2025
Q3 		$16.5M Buy
1,351,254
+313,205
+30% +$4.33M 0.53% 78
2025
Q2 		$11.7M Buy
1,038,049
+139,859
+16% +$1.71M 0.43% 89
2025
Q1 		$10.4M Buy
898,190
+62,140
+7% +$634K 0.47% 81
2024
Q4 		$7.08M Buy
836,050
+62
+0% +$642 0.27% 103
2024
Q3 		$9.68M Buy
835,988
+192,091
+30% +$2.42M 0.37% 88
2024
Q2 		$7.59M Sell
643,897
-27,279
-4% -$318K 0.32% 101
2024
Q1 		$7.96M Buy
+671,176
New +$8.95M 0.32% 102
2021
Q4 		– Sell
-304,113
Closed -$5.31M – 287
2021
Q3 		$5.31M Sell
304,113
-70,520
-19% -$1.43M 0.19% 115
2021
Q2 		$8.98M Sell
374,633
-22,650
-6% -$593K 0.33% 105
2021
Q1 		$10.2M Buy
+397,283
New +$10.4M 0.37% 104

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Emerald Advisers's KALV Position: Q1 2026 in Review

Emerald Advisers reduced its KalVista Pharmaceuticals (KALV) stake by 5.7% in Q1 2026, selling an estimated $1.23M and leaving 1,264,023 shares worth $25.4M. The position accounts for 0.81% of the portfolio, ranked #55.

Emerald Advisers first reported a position in KALV in Q1 2021 and has held it in 12 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Emerald Advisers held 1,264,023 shares of KalVista Pharmaceuticals worth $25.4M as of Q1 2026.
  • Emerald Advisers sold 76,472 KalVista Pharmaceuticals shares in Q1 2026, an estimated $1.23M.
  • KalVista Pharmaceuticals made up 0.81% of Emerald Advisers's portfolio in Q1 2026, its #55 holding.
  • Emerald Advisers first reported a position in KalVista Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Emerald Advisers's 13F filing for Q1 2026, filed 4 May 2026.